W W Hu

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Clin Cancer Res 5:3411-8. 1999
  2. ncbi request reprint Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Biol Blood Marrow Transplant 6:58-69. 2000
  3. ncbi request reprint Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
    L J Johnston
    Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
    Biol Blood Marrow Transplant 6:555-62. 2000
  4. ncbi request reprint Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer
    R S Negrin
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, California USA
    Biol Blood Marrow Transplant 6:262-71. 2000
  5. ncbi request reprint High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience
    T M Cao
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, California 94305-5623, USA
    Biol Blood Marrow Transplant 7:294-301. 2001
  6. ncbi request reprint Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation
    T M Dickson
    Department of Clinical Nutrition, Stanford University Medical Center, California 94305, USA
    Biol Blood Marrow Transplant 5:299-305. 1999
  7. ncbi request reprint Effect of oral glutamine supplementation during bone marrow transplantation
    T M Coghlin Dickson
    Department of Clinical Nutrition, Stanford University Medical Center, California 94305, USA
    JPEN J Parenter Enteral Nutr 24:61-6. 2000
  8. ncbi request reprint Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies
    T M Cao
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305-5623, USA
    Cancer 91:2205-13. 2001

Collaborators

Detail Information

Publications8

  1. ncbi request reprint A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Clin Cancer Res 5:3411-8. 1999
    ..G-CSF administration after each PBPC infusion appears to accelerate time to neutrophil recovery but does not affect red cell or platelet engraftment...
  2. ncbi request reprint Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy
    W W Hu
    Department of Medicine, Stanford University Medical Center, California 94305, USA
    Biol Blood Marrow Transplant 6:58-69. 2000
    ....
  3. ncbi request reprint Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
    L J Johnston
    Division of Bone Marrow Transplantation, Stanford University, California 94305, USA
    Biol Blood Marrow Transplant 6:555-62. 2000
    ..We conclude that HDSC/AHCT in refractory/recurrent NHL is associated with considerable acute and chronic toxicities. Given the toxicity profile, efficacy data were not sufficiently promising to warrant further study...
  4. ncbi request reprint Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer
    R S Negrin
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, California USA
    Biol Blood Marrow Transplant 6:262-71. 2000
    ..In summary, highly purified CD34+Thy-1+ cells used as the sole source of the hematopoietic graft result in rapid and sustained hematopoietic engraftment...
  5. ncbi request reprint High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience
    T M Cao
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, California 94305-5623, USA
    Biol Blood Marrow Transplant 7:294-301. 2001
    ..Lastly, patients with TFL or induction failure and relapsed FLCL can achieve survival outcome comparable to those observed with the indolent follicular lymphomas...
  6. ncbi request reprint Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation
    T M Dickson
    Department of Clinical Nutrition, Stanford University Medical Center, California 94305, USA
    Biol Blood Marrow Transplant 5:299-305. 1999
    ..We determined that dose adjustment could be safely used without significant increase of relapse. In patients with significant deviation of BMI from aBMI, dose adjustment and possible weight normalization should be considered...
  7. ncbi request reprint Effect of oral glutamine supplementation during bone marrow transplantation
    T M Coghlin Dickson
    Department of Clinical Nutrition, Stanford University Medical Center, California 94305, USA
    JPEN J Parenter Enteral Nutr 24:61-6. 2000
    ....
  8. ncbi request reprint Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies
    T M Cao
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305-5623, USA
    Cancer 91:2205-13. 2001
    ..However, the low-density selected cells still resulted in GVHD, and there was a high treatment-related mortality...